CDKN2A and neoplasm: Our results of reduced in vivo tumorigenesis in the late generation the mTERC−/−Cdk4R/R mutant mice are consistent with those of Khoo et al that report a decrease in tumor incidence and increases tumor latency in late-generation mTERC−/−Ink4a/Arf mutant mice [44].